Slide 1: Agreement to Acquire Biohaven
Agreement to Acquire Biohaven May 10, 2022 Breakthroughs that Biohaven Acquisition change Investor Call patients’ lives ® 1 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from those expresse
Slide 3: Today's Speakers
Today’s Speakers David Denton Angela Hwang Aamir Malik Vlad Coric Executive Vice President, Chief Group President, Pfizer Executive Vice President, Chief Chairman & Chief Executive Financial Officer, Pfizer Biopharmaceuticals Group Business Innovation Officer, Pfizer Officer, Biohaven Biohaven Acqui
Slide 4: For Q&A Session
For Q&A Session Nick Lagunowich Jim Rusnak Bill Sessa Global President, Internal Chief Development Officer, Internal Chief Scientific Officer, Internal Medicine Medicine & Hospital Medicine Biohaven Acquisition Investor Call 4 4
Slide 5: Transaction Overview
Transaction Overview Proposed acquisition builds on Pfizer’s heritage and legacy in delivering breakthroughs in Primary Care, Women’s Health and Pain • Pfizer will acquire all outstanding shares of Acquisition Assets Biohaven not already owned by Pfizer for $148.50 per share in cash, a ~33% premium
Slide 6: This Opportunity Delivers Breakthrough Potential and Enhances Growth Prospects
This Opportunity Delivers Breakthrough Potential and Enhances Growth Prospects Opportunity Strategic Fit Value Rationale Growth transaction; potential for Pfizer We focus on addressing some of the to profoundly accelerate growth and Significant unmet need; breakthrough world’s largest population hea
Slide 7: Pfizer Internal Medicine: Where High Science Meets High Prevalence
Pfizer Internal Medicine: Where High Science Meets High Prevalence Addressing health challenges that affect 52M Patients reached by our medicines in 2021* millions of lives around the world Migraine** Primary Care & Women’s Health Pipeline & Portfolio Cardiology & Additional Brands Growth Areas The
Slide 8: Migraine is One of the Most Prevalent Diseases Worldwide
Migraine is One of the Most Prevalent Diseases Worldwide Severe Attacks Are Categorized by WHO as Among the Most Disabling Illnesses 1B Patients suffer from Migraine Worldwide 11.6% WW prevalence “My children say US 40M sufferers they are going to grow up and become “this medicine is a life saver” “
Slide 9: Building on Biohaven Success with Continued Momentum with Regulatory Milestones
Building on Biohaven Success with Continued Momentum with Regulatory Milestones Rimegepant represents a breakthrough as the first and only treatment for patients suffering from acute and preventive episodic migraine Rimegepant Zavegepant Intranasal (acute) US, EU, UAE, Israel: Both Indications Appro
Slide 10: Nurtec ODT Key Performance Metrics
$124M 8% TRx $650M 2M 1Q 2022 NET SALES GROWTH 1Q22 v. 4Q21 NET SALES SINCE TRxs OF NURTEC® ODT LAUNCH to date BREAKING NEWS EU APPROVAL 96% 263M Decreased Opioid Use in COMMERCIAL LIVES Migraine Patients Post COVERAGE Nurtec ODT Therapy May 10, 2022 10
Slide 11: Growing Nurtec ODT Volumes through Trial and Adoption
Growing Nurtec® ODT Volumes through Trial and Adoption Drive Trial and Adoption of Nurtec ODT Patient Support Seasonality Volume Discounts Product Mix May 10, 2022 11
Slide 12: Key Nurtec ODT Co-Pay Seasonality Dynamics
Key Nurtec® ODT Co-Pay Seasonality Dynamics Patient Affordability Utilization by Quarter Blended Co-Pay Cost Per Claim by Month Q1 2022 Patient Affordability Utilization May 10, 2022 12
Slide 13: Oral CGRP Class Continues to Show Robust Market Growth
Oral CGRP Class Continues to Show Robust Market Growth Nurtec® ODT leads in TRx at 47.6% share 1. Total Rx Volume (4/22)¹ 2. Total Rx Share (4/22)1 32,874 Nurtec ODT 47.6% Nurtec ODT 28,290 Ubrelvy 41.0% Ubrelvy Prevention Approval 7,916 Qulipta 11.5% Qulipta 5/7 7/2 7/9 8/6 9/3 1/7 2/4 3/4 4/1 4/8
Slide 14: Oral CGRPs: Fastest Growing Class in Large U.S. Migraine Market
Oral CGRPs: Fastest Growing Class in Large U.S. Migraine Market 60.0% 50.0% Triptans % U.S. Migraine Market Share 40.0% Topiramate As of April 2022, CGRP Orals account 30.0% for 10% of migraine market TRxs 20.0% Total migraine market expected to grow to CGRP mAbs ~40+ million scripts 10.0% Oral CGRP
Slide 15: Oral CGRPs Have Significant Growth Opportunity Ahead vs Triptans + Topiramate
Oral CGRPs Have Significant Growth Opportunity Ahead vs Triptans + Topiramate TRx Volume vs Triptans + NBRx Volume vs Triptans + Topiramate¹ Topiramate² Quarterly Quarterly 6,968,342 TRx volume NBRx volume 955,069 18% 11% 167,835 790,980 1Q22 1Q22 1Q22 1Q22 CGRP orals3 Triptans + CGRP orals3 Triptan
Slide 16: Pfizer is Poised to Accelerate Oral CGRP Growth and Nurtec ODT Share by Winning in Primary Care
Pfizer is Poised to Accelerate Oral CGRP Growth and Nurtec ODT Share by Winning in Primary Care Scale and Expertise to Migraine Market Potential Build Best-in-Class Franchise 2x Double the number of sales representatives carrying Nurtec potentially reaching 70K additional 2021 oral CGRP share of Rx’
Slide 17: Business Development Strategy
Business Development Strategy Potential Business Development Two Deals Towards This $25B Ambition Could add at least... Global franchise peak sales, if successful, has $25B the potential to reach…(1) of risk-adjusted revenues to our 2030 top-line expectations >$6B (1) The proposed transactions are s
Slide 18: Key Takeaways
Key Takeaways ● Migraine is one of the most prevalent diseases worldwide, impacting ~1 billion patients ● Significant unmet need; severely impacting patients' daily functioning ability and overall quality of life ● Nurtec ODT is currently the #1 most prescribed oral CGRP ● Experience, scale, capabil
Slide 19: Q&A Session
Q&A Session And, while we navigate the important work and challenges of today, we Breakthroughs courageously that look towards theChange future to Patients’ continue toLives bring value to an unrivaled reach of patients. Biohaven Acquisition Investor Call Confidential 19